Edible Vaccine Market Report 2024

This Edible Vaccine market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The edible vaccine market size has grown strongly in recent years. It will grow from $8.04 billion in 2023 to $8.77 billion in 2024 at a compound annual growth rate (CAGR) of 9.1%. The growth during the historic period can be attributed to advancements in genetic engineering, challenges associated with traditional vaccines, progress in biopharming, a growing focus on global immunization efforts, and increased funding and support from governments.

The edible vaccine market size is expected to see strong growth in the next few years. It will grow to $12.5 billion in 2028 at a compound annual growth rate (CAGR) of 9.2%. The projected growth during the forecast period can be attributed to the increasing demand for pandemic preparedness, advancements in plant biotechnology, heightened public awareness and acceptance of genetically modified foods, efforts to address cold chain challenges, and integration with food security initiatives. Key trends anticipated during this period include expansion into animal health, greater utilization of biopharming, personalized nutrition and vaccination approaches, a focus on sustainability and green vaccines, and the development of multi-antigen edible vaccines.

The increasing prevalence of infectious diseases is anticipated to drive the growth of the edible vaccine market in the coming years. Infectious diseases are illnesses caused by harmful microorganisms, including bacteria, viruses, fungi, or parasites, that invade the body and multiply. The rise in infectious diseases is largely attributed to factors such as globalization, climate change, urbanization, and antibiotic resistance, which facilitate the spread and emergence of new pathogens. Edible vaccines offer a solution for combating infectious diseases by stimulating immune responses through the consumption of genetically modified foods that produce antigens, providing a cost-effective and needle-free immunization method. For instance, in March 2024, the Centers for Disease Control and Prevention (CDC), a U.S.-based public health agency, reported that the number of tuberculosis cases increased from 8,320 in 2022 to 9,615 in 2023, marking a rise of 1,295 cases. Additionally, the incidence rate per 100,000 people rose from 2.5 in 2022 to 2.9 in 2023. Therefore, the escalating prevalence of infectious diseases is a significant driver of the edible vaccine market.

Key companies in the edible vaccine market are concentrating on developing innovative solutions, such as oral cholera vaccines (OCVs), to address the global cholera crisis. OCVs are vaccines administered orally to prevent cholera, a severe diarrheal disease caused by the bacterium Vibrio cholerae. For example, in August 2024, Bharat Biotech International Limited, an India-based biotechnology company, launched Hillchol, an oral cholera vaccine with several advantageous features. This live-attenuated vaccine induces both systemic and mucosal immune responses, offering protection against cholera. Hillchol is notable for its ease of administration and the fact that it does not require cold storage, making it suitable for use in resource-limited settings. Additionally, it provides long-lasting immunity with just a single dose.

In May 2022, Ceva Santé Animale, a France-based pharmaceutical company, acquired Artemis Technologies Inc. for an undisclosed amount. This acquisition aims to strengthen Ceva Santé Animale's oral rabies vaccine portfolio and expand its presence in wildlife disease management. Artemis Technologies Inc. is a Canada-based company specializing in the provision of oral rabies vaccines.

Major companies operating in the edible vaccine market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., GSK plc, C.H. Boehringer Sohn AG & Co. KG, Novavax Inc., Ceva Santé Animale, Sinovac Biotech Ltd., Hualan Biological Engineering Inc., Zydus Lifesciences Limited, Bharat Biotech International Limited, Medicago Inc., CureVac N.V., Profectus BioSciences Inc., Vaxart Inc., China National Biotec Group Company Limited, Vaxine Pty Ltd., Vaxiion Therapeutics Inc., Therapix Biosciences Ltd., Mymetics Corporation.

North America was the largest region in the edible vaccine market in 2023. The regions covered in the edible vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the edible vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

An edible vaccine is a type of vaccine developed in genetically modified plants or animals, designed to be delivered through consumption rather than injection. These vaccines stimulate an immune response when an edible plant or food, such as fruits or vegetables, is consumed. This concept aims to provide a cost-effective and easily accessible alternative to traditional vaccines, particularly in developing countries.

The primary types of edible vaccines include inactivated vaccines, subunit vaccines, deoxyribonucleic acid (DNA) vaccines, live attenuated vaccines, and others. Inactivated vaccines are made from viruses or bacteria that have been killed or inactivated so they cannot cause disease, yet still elicit an immune response, such as the polio and hepatitis A vaccines. Distribution channels for these vaccines encompass hospitals, veterinary clinics, retail pharmacies, and online pharmacies. Their applications span medical care, livestock, aquaculture, agriculture, and more. Edible vaccines are utilized by a diverse range of end users, including adults, pediatric populations, and animals.

The edible vaccine market research report is one of a series of new reports that provides edible vaccine market statistics, including edible vaccine industry global market size, regional shares, competitors with a edible vaccine market share, detailed edible vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the edible vaccine industry. This edible vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The edible vaccine market consists of sales of plant-based edible vaccines, animal-based edible vaccines, algae-based edible vaccines, and yeast-based edible vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.